CBS62logoNEW2013_blue_final_header_White wwj950-sm2011b 971-ticket-35smb 35h_CBSSportsRad_Detroit

Aastrom Biosciences

aastrom

Aastrom Enrolls First Patients In Phase 2b Clinical Trial of Ixmyelocel-T

Aastrom Biosciences Inc. (Nasdaq:ASTM), the developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, today announced that the first patients have been enrolled in the ixCELL-DCM clinical trial.

WWJ Newsradio 950–04/04/2013

aastrom

Aastrom To Refocus Research On Dilated Cardiomyopathy, Cut Staff

Aastrom Biosciences Inc., a developer of patient-specific expanded multicellular therapies for the treatment of severe chronic diseases, announced a strategic change in its research and development programs to focus on the clinical development of its lead product, ixmyelocel-T, for the treatment of dilated cardiomyopathy.

WWJ Newsradio 950–03/27/2013

aastrom

Aastrom Board Names Dominick C. Colangelo President, CEO

Aastrom Biosciences Inc. announced that the company’s board of directors has named Dominick C. Colangelo as president and CEO.

WWJ Newsradio 950–03/07/2013

Doctor Checks Patient's Mouth

Stem Cell Therapy Could Offer New Hope For Head, Mouth Injuries, Defects

In the first human study of its kind, researchers found that using stem cells to re-grow craniofacial tissues — mainly bone — proved quicker, more effective and less invasive than traditional bone regeneration treatments.

WWJ Newsradio 950–08/05/2012

Follow

Get every new post delivered to your Inbox.

Join 1,884 other followers